[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fJbP_KYk-4ELygkWt1AqjVA62tzH8vrUi2AKEetQC3v0":8,"$fBSgeWasCPD9rpry86visB_XD3CopgQgdrNhvR5SJG9I":54,"$fj2OWx2bw7kOw81es-0YcbmSRBxYNjkX_pFeQxGLL9FA":58},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":53},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":6,"materialTotal":19,"videoTotal":20,"isConcern":7,"title":21,"coverVertical":17,"coverAcross":22,"content":23,"description":24,"views":25,"likes":20,"isThumbsUp":7,"isCollection":7,"collections":20,"createTime":26,"seoTitle":27,"seoKeywords":28,"seoDescription":29,"shelvesTime":30,"version":31,"menus":32,"menuId":34,"type":41,"quality":52,"commentCount":20,"isComment":6},57006,869827,[],"https://cdn.yishi-tong.com/console/store-15/XlbQ4LUNHG1U6MGzT0We2yFOV8tgQYO1.jpg","肺癌观察者","","肿瘤综合科",186,0,"突破肺癌治疗的蓝海：免疫疗法的奇迹与原理","https://ystcdn.venuertc.com/venue/AI/7a04777b-7441-442e-bba8-5450cd759a3c.jpg","\u003Cdiv class=\"material-container\">   \u003Ch1 id=\"material_title\" class=\"material-title\">突破肺癌治疗的蓝海：免疫疗法的奇迹与原理\u003C/h1>    \u003C!-- 01 肺癌的复杂面孔 -->   \u003Csection class=\"material-section material-bg1\">     \u003Ch2 class=\"material-subtitle\">01. 肺癌的复杂面孔\u003C/h2>     \u003Cdiv class=\"material-paragraph\">       \u003Cp>有时候，身边的朋友刚咳了两声，没几天就说医生建议做个肺部检查。其实，肺癌这类病并不像想象中离我们多远。全球范围内，肺癌每年夺走超过一百万人的生命（Sung et al., 2021）。\u003C/p>       \u003Cp>       肺癌类型主要分为 “非小细胞肺癌” 和 “小细胞肺癌”（WHO, 2021），前者大约占所有肺癌的85%。导致这种病的机制并不单一，涉及到肺部细胞基因异常、生长失控，还有与环境、遗传、年龄密切相关。小细胞肺癌虽然少见，却发展特别快，常常在发现时已经扩散到了其他器官。\u003C/p>     \u003C/div>     \u003Cdiv class=\"material-tips\">       \u003Cspan>🔍 \u003C/span>别忽视：初期肺癌常没太大感觉，轻微咳嗽或嗓子不舒服容易被误认成小感冒，实际已经是警钟敲响。     \u003C/div>   \u003C/section>     \u003C!-- 02 免疫系统与癌症：一场无形的斗争 -->   \u003Csection class=\"material-section material-bg2\">     \u003Ch2 class=\"material-subtitle\">02. 免疫系统与癌症：一场无形的斗争\u003C/h2>     \u003Cdiv class=\"material-paragraph\">       \u003Cp>         简单来讲，免疫系统就像体内的守卫检查站，识别并清除异常细胞。如果发现有“可疑分子”，比如基因突变的异常细胞，就会派出各种免疫细胞去处理。但肺癌这类肿瘤太狡猾，经常能伪装自己，让免疫系统难以发现。       \u003C/p>       \u003Ctable class=\"material-table\">         \u003Cthead>           \u003Ctr>             \u003Cth>免疫系统“守卫”\u003C/th>             \u003Cth>肺癌的“伪装”\u003C/th>           \u003C/tr>         \u003C/thead>         \u003Ctbody>           \u003Ctr>             \u003Ctd>T细胞（识别与攻击异常细胞）\u003C/td>             \u003Ctd>表达PD-L1分子，使T细胞以为它是“自己人”\u003C/td>           \u003C/tr>           \u003Ctr>             \u003Ctd>自然杀伤细胞\u003C/td>             \u003Ctd>通过分泌特殊信号分子迷惑免疫“监视”\u003C/td>           \u003C/tr>         \u003C/tbody>       \u003C/table>       \u003Cdiv class=\"material-case\">         \u003Cspan>💡 \u003C/span>有位58岁的女士，平时身体还算健康，但持续咳嗽、声音沙哑，后来检查才发现是免疫系统没能及时发现异常细胞，已发展为中晚期肺癌。这说明，癌症细胞伪装的能力确实不能小看。       \u003C/div>     \u003C/div>     \u003Cdiv class=\"material-tips\">       \u003Cspan>🛡️ \u003C/span>小心：肺癌喜欢制造复杂的“微环境”，让周围免疫细胞变得迟钝，早识别并不容易。     \u003C/div>   \u003C/section>     \u003C!-- 03 免疫治疗的历史与发展 -->   \u003Csection class=\"material-section material-bg3\">     \u003Ch2 class=\"material-subtitle\">03. 免疫治疗的历史与发展\u003C/h2>     \u003Cdiv class=\"material-paragraph\">       \u003Cp>说起来，早在上个世纪初，医生就尝试用疫苗来唤醒身体对癌症的免疫反应。到了1990年代，单克隆抗体的研发成为免疫治疗的新起点。21世纪，细胞疗法开始出现在临床，比如后来的CAR-T技术。\u003C/p>       \u003Cul class=\"material-list\">         \u003Cli>1890年代：首次尝试用细菌毒素刺激免疫反应（Coley's toxins）\u003C/li>         \u003Cli>1997年：单克隆抗体（如Rituximab）首次获批用于血液肿瘤\u003C/li>         \u003Cli>2010年代：PD-1/PD-L1等新一代免疫检查点抑制剂面世，开启肺癌免疫治疗的新纪元\u003C/li>       \u003C/ul>       \u003Cp>         免疫治疗如今已成为肺癌等实体肿瘤治疗的突破口（Sharma & Allison, 2015）。\u003C/p>     \u003C/div>     \u003Cdiv class=\"material-tips\">       \u003Cspan>📈 \u003C/span>别忽视：免疫治疗进步并不是一蹴而就，经历了数十年摸索才让更多患者受益。     \u003C/div>   \u003C/section>     \u003C!-- 04 免疫治疗的基本原理 -->   \u003Csection class=\"material-section material-bg4\">     \u003Ch2 class=\"material-subtitle\">04. 免疫治疗的基本原理\u003C/h2>     \u003Cdiv class=\"material-paragraph\">       \u003Cp>免疫治疗核心方法其实是让沉睡或被迷惑的“守卫”，重新认清癌细胞。最常见的技术当属“免疫检查点抑制剂”，比如针对PD-1或PD-L1的抗体药物（Nivolumab、Pembrolizumab等）。       \u003C/p>       \u003Cdl class=\"material-dl\">         \u003Cdt>免疫检查点抑制剂\u003C/dt>         \u003Cdd>阻断肿瘤伪装标记，让T细胞重新识别并攻击癌细胞。\u003C/dd>         \u003Cdt>CAR-T细胞疗法\u003C/dt>         \u003Cdd>提取患者自身免疫细胞，在体外改造后再回输，让它专门识别肿瘤特定标记。\u003C/dd>       \u003C/dl>       \u003Cp>         不同患者用药后效果差异不小（Hellmann et al., 2018），但对于部分晚期肺癌，确实为生存带来了转机。       \u003C/p>       \u003Cdiv class=\"material-case\">         \u003Cspan>✔️ \u003C/span>有位65岁的先生，晚期非小细胞肺癌，用免疫检查点抑制剂后肿瘤明显缩小，肺部症状缓解，这说明新疗法带来的希望不容小觑。       \u003C/div>     \u003C/div>     \u003Cdiv class=\"material-tips\">       \u003Cspan>🔬 \u003C/span>提醒：不是所有肺癌都适合免疫治疗，个体化方案才是关键。     \u003C/div>   \u003C/section>    \u003C!-- 05 免疫治疗的应用现状与挑战 -->   \u003Csection class=\"material-section material-bg5\">     \u003Ch2 class=\"material-subtitle\">05. 应用现状与挑战\u003C/h2>     \u003Cdiv class=\"material-paragraph\">       \u003Cp>         目前，肺癌免疫疗法已在国内外大医院广泛应用，尤其是免疫检查点抑制剂，常被用作晚期非小细胞肺癌的一线治疗（Herbst et al., 2020）。         这种疗法对一部分患者来说，是获得长期缓解的关键，但也并非万能之药。       \u003C/p>       \u003Ctable class=\"material-table\">         \u003Cthead>           \u003Ctr>             \u003Cth>优点\u003C/th>             \u003Cth>潜在挑战\u003C/th>           \u003C/tr>         \u003C/thead>         \u003Ctbody>           \u003Ctr>             \u003Ctd>部分患者肿瘤显著缩小\u003C/td>             \u003Ctd>约有40%~60%患者效果有限（Hellmann et al., 2018）\u003C/td>           \u003C/tr>           \u003Ctr>             \u003Ctd>副作用相对化疗温和\u003C/td>             \u003Ctd>可出现自身免疫问题，如皮疹、肺炎\u003C/td>           \u003C/tr>           \u003Ctr>             \u003Ctd>部分药物已纳入医保覆盖\u003C/td>             \u003Ctd>疗效高低与遗传、肿瘤分型有关\u003C/td>           \u003C/tr>         \u003C/tbody>       \u003C/table>       \u003Cdiv class=\"material-case\">         \u003Cspan>🧑‍⚕️ \u003C/span>一名55岁男士，接受免疫疗法后，虽然肿瘤稳定，但自觉有皮肤与关节不适。这个现象提示，治疗期间多科合作和耐心观察很重要。       \u003C/div>     \u003C/div>     \u003Cdiv class=\"material-tips\">       \u003Cspan>⚠️ \u003C/span>别忽视：疗效差异巨大，副作用要重视，选择正规医院和专业团队非常关键。     \u003C/div>   \u003C/section>    \u003C!-- 06 未来展望：个性化免疫治疗的可能性 -->   \u003Csection class=\"material-section material-bg6\">     \u003Ch2 class=\"material-subtitle\">06. 未来展望：个性化免疫治疗的可能性\u003C/h2>     \u003Cdiv class=\"material-paragraph\">       \u003Cp>未来肺癌治疗的理想图景，是把“大众方案”变成量身定制。从基因测序、蛋白分型，医生能分析每个人的“肿瘤密码”，制定个性化免疫疗法。\u003C/p>       \u003Cul class=\"material-list\">         \u003Cli>联合治疗：免疫+靶向+传统方案，让疗效更强。\u003C/li>         \u003Cli>免疫治疗后监测肿瘤微环境，调整药物，让不敏感的患者也有机会获益。\u003C/li>         \u003Cli>定期身体检查（如每年低剂量CT），高风险人群（比如长期吸烟者）更需关注肺部健康。\u003C/li>       \u003C/ul>       \u003Cdiv class=\"material-tips\">         \u003Cspan>🌱 \u003C/span>行动建议：饮食方面，多吃胡萝卜、奇异果等富含抗氧化物的食物，有助维护免疫状态，虽不能直接防癌，但对健康大有好处。       \u003C/div>     \u003C/div>     \u003Cdiv class=\"material-paragraph\">       \u003Cp>最好的办法是和专业医生保持沟通，选择适合自己的治疗和管理模式。科技发展很快，希望虽在前方，但脚步要扎实。\u003C/p>     \u003C/div>   \u003C/section>    \u003C!-- 文献引用 -->   \u003Csection class=\"material-section material-bg7\">     \u003Ch2 class=\"material-subtitle\">参考文献\u003C/h2>     \u003Cul class=\"material-ref-list\">       \u003Cli>         Sung, H., Ferlay, J., Siegel, R. L., et al. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. \u003Cem>CA: A Cancer Journal for Clinicians\u003C/em>, 71(3), 209-249. https://doi.org/10.3322/caac.21660       \u003C/li>       \u003Cli>         World Health Organization. (2021). Histological Classification of Lung Cancer. \u003Cem>International Agency for Research on Cancer\u003C/em>.        \u003C/li>       \u003Cli>         Sharma, P., & Allison, J. P. (2015). The future of immune checkpoint therapy. \u003Cem>Science\u003C/em>, 348(6230), 56-61. https://doi.org/10.1126/science.aaa8172       \u003C/li>       \u003Cli>         Hellmann, M. D., Ciuleanu, T. E., Pluzanski, A., et al. (2018). Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. \u003Cem>New England Journal of Medicine\u003C/em>, 378(22), 2093-2104.       \u003C/li>       \u003Cli>         Herbst, R. S., Baas, P., Kim, D.-W., et al. (2020). Pembrolizumab versus chemotherapy for previously untreated, PD-L1–expressing, locally advanced or metastatic non–small-cell lung cancer (KEYNOTE-024). \u003Cem>New England Journal of Medicine\u003C/em>, 375(19), 1823-1833.       \u003C/li>     \u003C/ul>   \u003C/section> \u003C/div>   \u003C!-- 独立全局样式  --> \u003Cstyle> .material-container {   font-family: \"PingFang SC\", \"Helvetica Neue\", Helvetica, Arial, \"Microsoft YaHei\", sans-serif;   line-height: 1.8;   color: #333;   max-width: 840px;   margin: 0 auto;   padding: 20px;   background: #fbfaf9;   border-radius: 16px;   box-shadow: 0px 3px 12px rgba(70, 70, 70, 0.07); } .material-title {   font-size: 2.2rem;   color: #1c2739;   font-weight: bold;   text-align: center;   padding-bottom: 16px;   letter-spacing: 2px; } .material-section {   margin-bottom: 32px;   padding: 24px 20px 18px 20px;   border-radius: 12px;   box-shadow: 0 1px 8px  rgba(120,120,120,0.03); } .material-subtitle {   font-size: 1.32rem;   font-weight: 600;   margin-bottom: 10px;   color: #254464;   letter-spacing: 1px;   display: flex;   align-items: center; } .material-bg1 { background: #e4eaef; } .material-bg2 { background: #e9f1e6; } .material-bg3 { background: #f4f4e1; } .material-bg4 { background: #e7edfe; } .material-bg5 { background: #faedea; } .material-bg6 { background: #fff7ed; } .material-bg7 { background: #f3f7f8; } .material-paragraph {   font-size: 1rem;   color: #394050;   margin-bottom: 8px; } .material-tips, .material-case {   margin: 12px 0 7px 0;   background: rgba(244,197,192,0.16);   color: #9b3f26;   font-size: 0.98rem;   padding: 7px 14px 7px 10px;   border-left: 3px solid #f4a382;   border-radius: 6px;   display: flex;   align-items: center; } .material-case {   background: rgba(224,235,250,0.18);   border-left: 3px solid #4e7dbe;   color: #3576a8; } .material-list {   padding-left: 16px;   margin: 6px 0 10px 0;   color: #3c4858; } .material-list li {   margin-bottom: 5px; } .material-table {   width: 100%;   border-collapse: collapse;   margin: 10px 0 12px 0;   font-size: 0.97rem;   background: #f8fafb;   border-radius: 6px;   overflow: hidden; } .material-table th, .material-table td {   border: 1px solid #e6e7ef;   padding: 7px 10px;   text-align: left; } .material-table th {   background: #e5ecf5;   color: #385479;   font-weight: 600; } .material-table td {   background: #fafbfc; } .material-dl {   margin: 10px 0 10px 0; } .material-dl dt {   font-weight: bold;   color: #245389;   margin-top: 8px;   margin-bottom: 3px; } .material-dl dd {   margin-bottom: 5px;   margin-left: 14px;   color: #394050; } .material-ref-list {   font-size: 0.96rem;   color: #3d5872;   line-height: 1.62;   padding-left: 12px; } .material-ref-list li {   margin-bottom: 8px; } @media (max-width: 650px) {   .material-container {     padding: 8px 2vw;     font-size: 0.91rem;   }   .material-section { padding: 10px 5vw 10px 5vw; }   .material-title { font-size: 1.35rem; } } \u003C/style>","文章探讨了肺癌的复杂性质及免疫系统与癌症的斗争，详细介绍了免疫治疗的发展历史、基本原理及应用现状，展望未来个性化免疫治疗的可能性，提供治疗与管理的科学建议。",468,"2025-08-08 10:26:54","突破肺癌治疗的蓝海：免疫疗法的奇迹与原理 | 最新癌症治疗进展  ","肺癌免疫疗法,癌症免疫治疗,PD-1抑制剂,CTLA-4疗法,肿瘤微环境,免疫检查点,肺癌靶向治疗,免疫治疗原理,肺癌突破性疗法  ","深度解析肺癌免疫疗法的革命性突破，揭秘PD-1/CTLA-4等免疫检查点抑制剂如何激活人体免疫系统精准杀伤癌细胞，探讨免疫疗法为晚期肺癌患者带来的生存奇迹与最新临床进展。","2025-08-14 14:50:00",2,[33],{"menuId":34,"menuName":35,"parentId":20,"orderNum":31,"path":36,"component":37,"isFrame":38,"isCache":39,"menuType":40,"visible":41,"status":20,"createDept":6,"remark":17,"createTime":42,"children":43,"columnImage":44,"columnLogo":45,"uncheckedLogo":6,"checkedLogo":6,"isHot":41,"isHome":20,"forceLogin":20,"color":46,"seoTitle":47,"seoKeywords":48,"seoDescription":49,"contentNum":6,"promotionalPoster":50,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":51,"routerPath":36,"componentInfo":37},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":55,"success":53},{"pageNo":41,"pageSize":56,"result":57,"totalSize":20},10,[],{"code":9,"msg":10,"message":6,"data":59,"success":53},{"authors":60,"appraiseDimensionScoresVos":61},[],[]]